Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

OCTOBER 4, 2021

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. Department of Justice, which can change as the political winds or officeholder changes—as occurred in the case of cannabis.

Therapy 52

Therapy Patients Law Clinical Trials 52

CannaMD

SEPTEMBER 15, 2020

SHORT ANSWER: In November 2016, the Florida Medical Marijuana Legalization Initiative (known as Amendment 2 ) legalized medical marijuana treatment in Florida. Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Qualified patient.

Law 126

Law Marijuana Patients Treatment 126

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. Therefore, it no longer meets the criteria for placement in Schedule I. While … Keep reading.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

Cannabis Law Report

JUNE 11, 2021

In turn, here are the top 6 questions we’ve been getting lately around ketamine clinics: Isn’t the regulation of ketamine clinics just like adult-use/medicinal cannabis businesses? Pursuant to the federal Controlled Substances Act, cannabis is an illegal schedule I controlled substance while ketamine is on schedule III. No, it’s not.

Law 104

Law Compliance Compliance DEA 104

Veriheal

AUGUST 24, 2022

This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers.

Legalization 99

Legalization Decriminalization Medicine Research and Development 99

MedicalJane

JUNE 29, 2018

None of the approved drugs contain, or are derived from, the whole cannabis plant. The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. a Canada-based medical cannabis firm.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

NewsMunchies

NOVEMBER 12, 2021

As the cannabis industry continues to grow and evolve with legalization achieved in many parts of the world, we’re seeing an increase in activity related to another substance that will hopefully be removed from the list of controlled substances – psilocybin. We know such categorization is baseless and false. Rate this blog post.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. Under the cannabis category, there are 61 options. Is cannabis actually. Green or not?

Research and Development 52

Research and Development Events Topical Policy 52

Veriheal

JUNE 24, 2021

The director was spoken to regarding psychedelics and cannabis by Senator Brian Schatz during a Senate Appropriations subcommittee hearing. Collins responded that they have made “some progress” but that the schedule 1 listing of the substances causes researchers to have to “overcome significant hurdles to access it”. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

Cannabis Law Report

FEBRUARY 28, 2022

Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. TIMES (Nov. Feduccia et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Drug Enforcement Agency (“DEA”). The federal government and most of the states in the U.S.

Law 105

Law Therapy Clinical Trials Research and Development 105

SpeedWeed

MARCH 25, 2021

A long-awaited clinical trial on using cannabis as a treatment for veterans with PTSD has finally been published in the PLOS One journal , but the results are far less promising than researchers and veterans had hoped. grams of cannabis flower or a placebo every day for 3 weeks. Each subject was asked to smoke 1.8

DEA 52

DEA Clinical Trials THC Pharmaceutical 52

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MAY 31, 2022

Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression. Though, Oregon is actively in the process of establishing a model for psilocybin that would be like the state’s current medical cannabis system. On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Veriheal

DECEMBER 27, 2022

In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. . The participants completed a survey asking about lifetime experiences with: Psychedelics (LSD, psilocybin, DMT, mescaline).

Research and Development 79

Research and Development Therapy Consumption DEA 79

Cannabis Law Report

APRIL 14, 2022

Cannabis cultivation and processing are rapidly-growing industries, as hemp and both recreational and medical marijuana products are being legalized across the country. by eating or smoking cannabis) are unknown. Since growing cannabis has not always been legal, growers did not always choose pesticides that were “approvable” by EPA.

Environment 52

Environment Agriculture Compliance Compliance 52

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. One group self-administered cannabis with 12% THC over three weeks.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

CannaMD

MAY 6, 2020

Just like using medical marijuana in residential apartments , traveling with cannabis comes down to federal versus state law. Since federal law supersedes state law, this also means that taking cannabis across state lines (even if both states permit medical marijuana use) is illegal. In practice, however, it’s very ambiguous.

Hash 103

Hash Legalization Marijuana Concentrates 103

The Joint Blog

JUNE 4, 2021

The United States Food and Drug Administration (FDA) has only cannabis use to treat two rare and severe forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous. Cancer pain.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Cannabis Law Report

SEPTEMBER 23, 2021

Tracking recent data from within the last year (following the publication of the DEA Interim Final Rule which added confusion to the delta-8 legality question), more than a dozen hospital or emergency room visits and hundreds of calls to poison control were reported. Delta-8 THC products should be kept out of the reach of children and pets.

THC 52

THC Concentrates Pets DEA 52

MedicalJane

OCTOBER 5, 2017

Standard treatment for severe cramps and pain. An over-the-counter medication like Midol, or an NSAID like ibuprofen, are conventional treatments that are commonly used to treat mild symptoms of menstrual cramps. So where are women to turn for natural, alternative forms of treatment that may provide relief?

Marijuana 65

Marijuana Treatment Extraction Medicine 65

Canna Law Blog

MAY 1, 2024

Yesterday, some big news dropped that the cannabis industry has anticipated since last summer. I take issue with some of the headlines , so here’s mine: “DEA Reportedly Agrees to Initiate Proposed Rulemaking to Reschedule Marijuana…”. I mentioned above that DEA “reportedly” has agreed to follow the HHS proposal.

DEA 70

DEA Marijuana Business Banking 70

Cannabis Law Report

JUNE 15, 2021

Reinvests funds to support programs that work on expanding access to substance use treatment, support harm reduction services, and reduce the criminalization of individuals who use drugs by supporting the development or expansion of pre-arrest diversion programs.

Decriminalization 78

Decriminalization Policy Research and Development Data 78

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. Patients Are Not In This Alone.

Therapy 53

Therapy DEA Patients Clinical Trials 53

Cannabis Law Report

JANUARY 30, 2019

Access the full document at. For nearly fifty years, the University of Mississippi has had the sole contract with the National Institute on Drug Abuse (NIDA) to grow cannabis for research purposes. Access the full document at. We’ve quickly scanned the document and highlight a few of the following passages of relevance.

Research and Development 63

Research and Development DEA CBD Law 63

Canna Law Blog

OCTOBER 29, 2019

Plans must also ensure that samples are representative of an entire hemp lot and the state or tribal agency charged with testing must have unrestricted access to all land, building, and structures used for the cultivation, handling, and storage of hemp. Labs that test cannabis for THC levels must be registered with the DEA.

Hemp 66

Hemp THC Compliance Compliance 66

Canna Law Blog

NOVEMBER 3, 2023

The lawsuit filed on October 26 against Merrick Garland to “end federal cannabis prohibition” wouldn’t really end federal cannabis prohibition. A victory would help cannabis operators who are drawing within the lines, as long as they stay within those lines. Many of the headlines are incomplete or downright misleading.

Topical 111

Topical DEA Cannabis State Laws 111

PrestoDoctor

JANUARY 14, 2020

For individuals who need marijuana or cannabis for medical reasons, they must get an MMJ. They are responsible for giving you information about the treatment and proper use. You may also submit it at a later date by accessing your online account. The DEA does not know who has MMJs and no consolidated database exists.

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

For individuals who need marijuana or cannabis for medical reasons, they must get an MMJ. They are responsible for giving you information about the treatment and proper use. You may also submit it at a later date by accessing your online account. The DEA does not know who has MMJs and no consolidated database exists.

Marijuana 52

Marijuana Patients Conditions Programs 52

Canna Law Blog

NOVEMBER 6, 2021

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. Psilocybin’s federal status as a Schedule I controlled substance is to blame. For two decades, U.S.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

SEPTEMBER 1, 2021

FEDERAL TAXATION OF CANNABIS: A PRIMER. The manufacture, distribution, and possession of cannabis is illegal under federal law, which categorizes it as a Schedule 1 controlled substance. states have therefore, in one form or another, defied federal law with respect to cannabis use and distribution in their respective jurisdictions.

Policy 100

Policy Cannabis Treatment Law 100

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. According to the Feds, ketamine is safer than cannabis (which is a Schedule I controlled substance). From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

MAY 17, 2019

PUBLISHER: CANNABIS LAW REPORT. . Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. A fast-growing, sustainable, and inexpensively produced plant, “Industrial Hemp” is a variety of Cannabis sativa L. Beyond removing plant cannabis sativa L.

Food 10

Food DEA Hemp CBD 10

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. of the global population uses cannabis annually, making it the most commonly used drug worldwide. It should be noted that cannabis and marijuana are not interchangeable terms.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40